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Background
The parent acceptable symptom state (PASS) constitutes
the symptom threshold beyond which parents consider
their child' health status as satisfactory. The PASS repre-
sents an ambitious target for disease management.
Objective
To devise and validate the PASS in patients with JIA.
Methods
369 parents completed a multidimensional questionnaire
(the JAMAR), including Juvenile Arthritis Functionality
Scale (JAFS) (score 0–30), Pediatric Rheumatology Qual-
ity of Life (PRQL) questionnaire (score 0–30) and tradi-
tional JIA outcome measures, and stated whether they
considered their children's status satisfactory or not. PASS
thresholds were estimated based on parent opinion and
targeting the 75th percentile of cumulative distribution.
Stepwise logistic regression was used to assess contribu-
tors to PASS. PASS was validated by analyzing proportions
of patients who were judged by parent or physician in
remission, flare or continued activity.
Results
72.9% of parents reported their children being in PASS
(table 1).
Conclusion
We devised the PASS for JIA. The PASS demonstrated good
validity by discriminating strongly between patients in
remission or active disease.
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Table 1: The PASS threshold
Parent global Parent pain JAFS PRQL MD global Active joints Limited joints
75° centile 2 1.5 1 4 1.5 1 1
Parent global (OR 4.6), PRQL (3.9), JAFS (4.0), MD global (2.6) and CRP (3.9) were the strongest contributors of PASS in logistic regression analysis 
(AUC: 0.92). Among patients judged in remission, flare or continued activity by the parent and physician, the percentage of those in PASS was 98, 
46 and 49 (p < 0.0001), and 93, 57 and 27 (p < 0.0001), respectively.